X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    New treatment for advanced and hormone refractory prostate cancer (HRPC) with an oral cholesterol derivative (hydroxysterol 24-ethyl-cholestane- 3β,5α,6α-triol).
    American Society of Clinical Oncology (ASCO) ; 2017
    In:  Journal of Clinical Oncology Vol. 35, No. 15_suppl ( 2017-05-20), p. e16531-e16531
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e16531-e16531
    Abstract: e16531 Background: Hydroxysterols and oxysterols are oxygenated derivatives of cholesterol. They are involved in the regulation of some aspects of neoplastic cell growth and proliferation, as demonstrated in vitro in a variety of human cancer cells including prostate cancer cells.These effects can be dependent on the activation of the oxysterol-binding liver X receptors (LXRs). LNCaP prostate tumor cells stimulated with synthetic LXR agonists showed G 1 to S-phase cell cycle arrest through the suppression of Skp2.Prostate cancer is the most frequent cancer in men and most patients become resistant to upfront treatments with hormones. At advanced stages most refractory patients are symptomatic and their life expectancy is limited. (24-ethyl-cholestane- 3β,5α,6α-triol) is a new hydroxysterol developed by us. It is the first oxysterol to be tested in the clinic. It is also one of the safest in this class of compounds. Methods: We have treated with this new drug 14 patients suffering from advanced and hormone-refractory prostate cancer (HRPC). Their median age was 73 (60-88). Seven with a Gleason 7, 5 with a Gleason 8 and 2 with a Gleason 9. Eleven had stage IV disease, Eight with bone metastasis, 4 with advanced loco-regional disease and 2 with visceral metastasis. Ten patients were symptomatic. Four patients had received also 1 line of chemotherapy and 2 others received 2 lines of chemo. Four patients were also previously treated with radiotherapy. Patients received daily 10 mg/Kg of oral (24-ethyl-cholestane- 3β,5α,6α-triol) divided into 3 equal doses, until disease progression. Results: Ten patients experienced either a biological or a radiological partial response (PR), Two patients had a stable disease (NC) and two patients had a disease progression (PD). The median duration of response was 2 years. Patients did not report any side-effect from treatment. Eighty percent of symptomatic patients had a remarkable symptom control. Conclusions: These encouraging results make this new and safe drug a good candidate for further clinical trials either alone or in combination with other drugs in the treatment of HRPC.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2017.35.15_suppl.e16531
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2017
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 2
    Online Resource
    Online Resource
    The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey
    Future Medicine Ltd ; 2021
    In:  Future Oncology Vol. 17, No. 2 ( 2021-01), p. 151-157
    Details
    In: Future Oncology, Future Medicine Ltd, Vol. 17, No. 2 ( 2021-01), p. 151-157
    Abstract: Lay abstract Cancer of unknown primary site (CUP) is a rare occurrence in which doctors identify where a cancer has spread but cannot determine where it originated. The rising cost of cancer care, particularly in patients with CUP, poses a significant challenge for low- and middle-income countries. To inform future guidelines, we conceived a survey of 20 items that focused on the diagnostic tests that doctors use for patients with CUP, as well as the treatment options that they could offer. Only participants from lower- and higher-middle-income countries, as per the World Bank Classification, were eligible for this study. Our results show that the indications for the first round of treatment were similar between the two income brackets, whereas those for the second round of treatment were more prevalent in higher-middle-income countries. The use of targeted therapy based on only one diagnostic test was higher in lower-middle-income countries, despite access to certain indicators of CUP being similar between the two regions.
    Type of Medium: Online Resource
    ISSN: 1479-6694 , 1744-8301
    URL: Article
    DOI: 10.2217/fon-2020-0677
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2021
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 3
    Online Resource
    Online Resource
    Activity of an oral hyroxysterol.
    American Society of Clinical Oncology (ASCO) ; 2017
    In:  Journal of Clinical Oncology Vol. 35, No. 15_suppl ( 2017-05-20), p. e20587-e20587
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e20587-e20587
    Abstract: e20587 Background: Hydroxysterols are oxygenated derivatives of cholesterol. They have been shown to interfere with proliferation and cause the death of many cancer cell types, such as leukaemia, glioblastoma, colon, breast and prostate cancer cells. They control the transcription and the turnover of the key enzyme in cholesterol synthesis. Hydroxysterols interfere with PI3K/AKT, MAPK/ERK, hedgehog and Wnt pathways of proliferation and differentiation. When administered in vitro to cancer cell lines, hydroxysterols invariably both slow down proliferation and provoke cell death. Many of these compounds show antitumor activity in experimental models and most of them are very toxic. (24-ethyl-cholestane- 3β,5α,6α-triol) is the first oxysterol being tested in the clinic. It is also one of the safest in this class of compounds. Methods: We have treated with this new drug 18 patients suffering from Non-small cell lung cancer (NSCLC); sixteen males and two females. Thirteen had adenocarcinomas and five had squamous-cell carcinoma. The median age was 65. Sixteen patients had a stage IV disease and two had a stage III disease. Seven had a PS: 1, seven had a PS: 2 and four had a PS:3. Seventy-five percent were symptomatic and fifty percent were taking pain killers. Six patients only did not receive previous chemotherapy and five received radiotherapy. Patients received daily 10 mg/Kg of oral (24-ethyl-cholestane- 3β,5α,6α-triol) divided in 3 equal doses, until disease progression. Results: Twelve patients had a partial response (PR), three patients had a stable disease (NC) and three patients had a disease progression (PD). The median duration of response was 8 months but 2 patients are still under treatment. No toxicity was observed so ever. Seventy-five percent of symptomatic patients had a remarkable symptom control. Conclusions: These encouraging results make this new and safe drug a good candidate for further clinical trials either alone or in association with other drugs for the treatment of NSCLC.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2017.35.15_suppl.e20587
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2017
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 4
    Online Resource
    Online Resource
    A cholesterol derivative (oxysterol; 24-ethyl-cholestane-3β, 5α, 6α-triol) with high antitumor activity against a variety of sarcomas.
    American Society of Clinical Oncology (ASCO) ; 2012
    In:  Journal of Clinical Oncology Vol. 30, No. 15_suppl ( 2012-05-20), p. e20500-e20500
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e20500-e20500
    Abstract: e20500 Background: Oxygenated derivatives of cholesterol, oxysterols, have different physicochemical properties acting on cell membranes. Agents belonging to this class of compounds have been found to induce apoptosis and to harbor antitumor activity demonstrated in vitro and in vivo. 24-ethyl-cholestane- 3β, 5α, and 6α-triol is a new oxysterol developed in our lab. Unlike other derivatives, it is, to our knowledge, the first tested in the clinic. Methods: We have previously reported encouraging and rapid results observed in patients suffering from a variety of solid tumors with an improvement of their quality-of- life and without side- effects. We have treated eight patients suffering from different types of sarcomas on a compassionate basis because we did not have any ongoing trial in sarcomas. Furthermore, most of these patients would not have been eligible for a clinical trial because of their bad performance-status. Three patients were suffering from carcinosarcomas, one from angiosarcoma, one from osteosarcoma, one from chondrosarcoma, one from undifferentiated sarcoma and one from Ewing sarcoma. Most of them were pretreated with chemotherapy and radiotherapy and most of them were in bad clinical conditions. Seven patients were females and one male with ages ranging from 21 to 82 (median age 55y). Results: None of these 8 patients experienced any side-effect despite the fact that one of them was taking a mild chemotherapy in association with oxysterol. This patient was excluded from the evaluation of the response to therapy. Among the 7 patients evaluable for response, we observed 4 complete responses (one of them confirmed by PET scan), two stable diseases and one progressive disease. The complete responses were observed in one osteosarcoma, one Ewing sarcoma, one angiosarcoma and one carcinosarcoma. As with our previous experience with this drug, no clinical or biological side-effect was observed and symptom control was achieved rapidly in all 6 symptomatic patients. Conclusions: We believe that this new compound deserves to be tested in phase II trials in patients suffering from sarcomas.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2012.30.15_suppl.e20500
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2012
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages